Kinetics of neutralising antibodies against SARS-CoV-2 variants

2024-9-1

Global, regional, and national burden of upper respiratory infections and otitis media, 1990–2021: a systematic analysis from the Global Burden of Disease Study 2021

2024-9-1

ArboTracker: a multipathogen dashboard and data platform for arbovirus seroprevalence studies

2024-9-1

The worsening mpox outbreak in Africa: a call to action

2024-9-1

Mpox outbreak—tecovirimat resistance, management approaches, and challenges in HIV-endemic regions

2024-9-1

Health outcomes 3 months and 6 months after molnupiravir treatment for COVID-19 for people at higher risk in the community (PANORAMIC): a randomised controlled trial

2024-9-1

SARS-CoV-2 antivirals and post-COVID-19 condition

2024-9-1

Burden of upper respiratory infections and otitis media

2024-9-1

Mpox emergency in Africa

2024-9-1

Safety and immunogenicity of a live-attenuated chikungunya virus vaccine in endemic areas of Brazil: interim results of a double-blind, randomised, placebo-controlled phase 3 trial in adolescents

2024-9-1

Weighing up monoclonals and vaccination against COVID-19

2024-9-1

Research in brief

2024-9-1

Setbacks and advances in the global HIV response

2024-9-1

Limited progress towards immunisation targets in 2023

2024-9-1

Real-time estimation of immunological responses against emerging SARS-CoV-2 variants in the UK: a mathematical modelling study

2024-9-1

Polio vaccination campaign in Gaza

2024-9-1

Potential vertical transmission of Oropouche virus during the current outbreak

2024-9-1

Safety and immunogenicity of mRNA-based seasonal influenza vaccines formulated to include multiple A/H3N2 strains with or without the B/Yamagata strain in US adults aged 50–75 years: a phase 1/2, open-label, randomised trial

2024-9-1

Limitations of mpox lateral flow tests in assessing orthopoxvirus immunity

2024-9-1

Shorter antibiotic courses for respiratory tract infections

2024-9-1

Global Sanitation Summit 2024

2024-9-1

First report from the UK COVID-19 Inquiry

2024-9-1

Chad eliminates gambiense sleeping sickness

2024-9-1

Effect of timing of casirivimab and imdevimab administration relative to mRNA-1273 COVID-19 vaccination on vaccine-induced SARS-CoV-2 neutralising antibody responses: a prospective, open-label, phase 2, randomised controlled trial

2024-9-1

The epidemiology, transmission, diagnosis, and management of drug-resistant tuberculosis—lessons from the South African experience

2024-9-1

First immunogenicity and safety data on live chikungunya vaccine in an endemic area

2024-9-1

The evidence base for the optimal antibiotic treatment duration of upper and lower respiratory tract infections: an umbrella review

2024-9-1

Next-generation influenza vaccines based on mRNA technology

2024-9-1

Facing COVID-19 in South Africa

2024-9-1

Emergence of an extensively drug-resistant Neisseria gonorrhoeae clone

2024-9-1

Phyllis Dako-Gyeke

2024-9-1

Amanda Kvalsvig—from paediatrics to epidemiology

2024-8-23

Infectious disease surveillance update

2024-8-23

Strongyloides stercoralis hyperinfection syndrome

2024-8-23

Brazil to distribute paediatric antimalarial in Amazon

2024-8-23

Waiting is no longer an option for household contacts of people with drug-resistant tuberculosis

2024-8-23

Oropouche fever, the mysterious threat

2024-8-8

Effectiveness of rVSV-ZEBOV vaccination during the 2018–20 Ebola virus disease epidemic in the Democratic Republic of the Congo: a retrospective test-negative study

2024-8-1

The global alarm bell is ringing due to the threat of potential severe cases and deaths caused by clade I of monkeypox virus

2024-8-1

Oropouche virus genomic surveillance in Brazil

2024-8-1

Immunogenicity and safety of an ORF7-deficient skin-attenuated and neuro-attenuated live vaccine for varicella: a randomised, double-blind, controlled, phase 2a trial

2024-8-1

Two dose levels of once-weekly fosravuconazole versus daily itraconazole in combination with surgery in patients with eumycetoma in Sudan: a randomised, double-blind, phase 2, proof-of-concept superiority trial

2024-8-1

Gavi, the Vaccine Alliance supports rabies vaccination

2024-8-1

Lessons learnt from conducting a randomised clinical trial in eumycetoma

2024-8-1

Correction to Lancet Infect Dis 2024; 24: e484

2024-8-1

Edging towards a third dengue vaccine

2024-8-1

Understanding outbreak preparedness

2024-8-1

Tuberculosis in the USA in 1935

2024-8-1

Ebola virus disease mathematical models and epidemiological parameters: a systematic review

2024-8-1

A persistent vesiculo-pustular rash, eosinophilia, and itchy parents: think of scabies

2024-8-1